Purpose—To critically review and evaluate the science behind individual eligibility criteria
(indication/inclusion and contraindications/exclusion criteria) for intravenous recombinant …

Background and Purpose—Since Food and Drug Administration approval of intravenous
tissue-type plasminogen activator (tPA) for treatment of acute ischemic stroke in 1996, it has …

Background Although National Institutes of Health Stroke Scale (NIHSS) is a known
predictor of outcome in acute ischemic stroke, there are other factors like age, ambulatory …

Introduction Despite increasing evidence of its efficacy in advanced age or in mild or severe
strokes, intravenous thrombolysis remains underused for acute ischaemic stroke (AIS). Our …

Background and Purpose—Several studies have reported poor outcomes in patients too
good to treat with intravenous thrombolysis because of mild or rapidly improving symptoms …

Objectives Approximately, half of the acute stroke patients with minor symptoms were
excluded from thrombolysis in some randomized controlled trials (RCTs). There is little …

Background: Thrombolysis is often withheld from acute ischemic stroke patients presenting
with mild symptoms; however, up to 40% of these patients end up with a poor outcome when …

Safety and Outcome of Thrombolysis in Mild Stroke: A Meta-Analysis - PMC Back to Top Skip to
main content NIH NLM Logo Access keys NCBI Homepage MyNCBI Homepage Main Content …

Acute ischemic stroke is a medical emergency requiring urgent treatment. Randomized
clinical trial and Phase IV data have provided unequivocal evidence that intravenous …

BACKGROUND: Intravenous tissue plasminogen activator (IV tPA) improves neurologic
outcome after stroke, but is not recommended for patients with minor neurologic deficits …